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use, and recipient age are not. Multivariable analysis was
challenging given the correlation among covariates.
However, male donor is signiﬁcantly associated with
improved OS for pts with grade 3-4 aGVHD in all models,
while time pd is not signiﬁcant when adjusting for other
factors.
Conclusions: While OS for pts with grade 3-4 aGVHD has
improved, it continues to impact >13% of pts and has poor
outcomes. The use of a male donor may predict improved OS
for pts with grade 3-4 aGVHD independent of time pd.
Additional study is warranted to validate these ﬁndings and
improve therapies.425
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Risk of acute GVHD varies among different ethnic population.
Thus, we evaluated potential differences in cGVHD mani-
festations in two ethnic distinct cohorts. The study included
a Brazilian cohort diagnosed with cGVHD by 2005 NIH
criteria who were enrolled in a prospective multicenter
longitudinal study at 5 centers in Brazil and compared with
a North American cohort reported by the cGVHD consortium
(Arai S. et al. Blood 2011). Pts. were assessed using stan-
dardized clinical data forms every 3 months (124 visits). Any
elevation of liver function tests was scored as cGVHD. The
Brazilian study cohort included 36 pts. with a median age of
44 (13-64) years and 21 (58%) were male. At study enroll-
ment, 24 (67%) had classic cGVHD, and 12 (33%) pts. had
overlap subtype (with feature of both acute and chronic).
Distribution of organ involvement attributed to cGVHD for
the Brazilian and the North American cohorts at study
enrollment is shown in the Figure. Liver severity scores at
study enrollment was mild in 10 (34%), moderate in 12 (40%)
and severe in 8 (26%) pts. among Brazilian cohort, and it was
mild in 113 (76%), moderated in 36 (24%) and none severe in
the North American cohort. Overall, cGVHD global severity at
study enrollment was calculated from reported data as mild
in 2 (5.5%), moderate in 17 (47%) and severe in 17 (47%) of
Brazilian cohort compared to 32 (10%),175 (59%) and 91(31%)
in the North American cohort, respectively. Similar to North
American cohort, distribution of global severity was similar
in the Brazilian cohort across 22 incident (enrollment < 3
months of cGVHD diagnosis) and 14 prevalent cases
(enrollment 3 or 6 months after cGVHD diagnosis) and,
between pts. with classic and overlap cGVHD. Prevalence of
organs involvement at study enrollment was signiﬁcant
different between the two population. Compared to theNorth American cohort, the Brazilian cohort had higher rates
of liver involvement (83% vs. 50%; p < .001) and lower rate of
lung (8% vs. 50%; p < .001), respectively. The cause for the
high incidence and severity scores in the liver among the
Brazilian cohort is unknown, but we speculated potential
contributors. For instance, 100% of Brazilian cohort was CMV
positive and pre-emptive treatment for CMV reactivation is
not used after day 100 posttransplant, thus reactivation of
CMV may have contributed to the elevation of liver function
tests. Moreover, it is not standard practice in Brazil to add
ursodiol to treat elevation of liver tests attributed to GVHD,
thus allowing for further potential increase in liver severity
score. The lower rates of lung in the Brazilian cohort may
reﬂect non-standardization of pulmonary function test in
Brazil. In conclusion, prevalence of organ manifestations in
cGVHD varied between the two ethnic distinct cohort
studied. Attention should be taken into consideration when
evaluating prognosis and outcomes in cGVHD in different
ethnic population.
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Background: Acute graft-versus-host disease (aGVHD) is
a frequent complication of allogeneic hematopoietic stem
cell transplantation (HSCT). Although the presence of a skin
eruption is a cornerstone in the diagnosis of aGVHD
according to the Glucksberg criteria and the 2005 NIH
Consensus Conference, speciﬁc cutaneous features such as
morphology and anatomic distribution have not been
studied in a systematic manner. Subsequently, the relative
incidences of speciﬁc skin lesions remain unclear and
contribute to the ongoing challenge of delineating aGVHD
from other commonly seen skin eruptions early after HSCT.
Methods: A retrospective review of all patients receiving an
allogeneic HSCT from 2010 to 2011 at Northwestern Memo-
rial Hospital identiﬁed those individuals with cutaneous
aGVHD. Each case of aGVHD was conﬁrmed by both skin
